Idenix Pharmaceuticals, Inc. (IDIX) Reports Third Quarter and Nine Month 2012 Financial Results and HCV Program Update  
11/2/2012 7:39:53 AM

CAMBRIDGE, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2012 and provided an update of its hepatitis C virus (HCV) development programs.